Johnson & Johnson (NYSE:JNJ) is Hendershot Investments Inc.’s 3rd Largest Position

Hendershot Investments Inc. raised its position in Johnson & Johnson (NYSE:JNJGet Rating) by 1.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 140,015 shares of the company’s stock after buying an additional 1,335 shares during the period. Johnson & Johnson accounts for 3.8% of Hendershot Investments Inc.’s investment portfolio, making the stock its 3rd biggest holding. Hendershot Investments Inc.’s holdings in Johnson & Johnson were worth $24,815,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNJ. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $34,000. Professional Financial Advisors LLC grew its stake in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares in the last quarter. Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $38,000. Finally, Advocacy Wealth Management Services LLC grew its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $165.30 on Friday. The business’s fifty day simple moving average is $174.47 and its two-hundred day simple moving average is $174.68. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a market cap of $434.60 billion, a price-to-earnings ratio of 24.06, a P/E/G ratio of 3.24 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the business posted $2.48 EPS. Research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. UBS Group cut their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *